Li Liang
Psychiatry · San Diego, CANPI 1053468546
Payments from drug & device makers
Across 480 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$971
- Sunovion Pharmaceuticals Inc.$744
- Takeda Pharmaceuticals U.S.A., Inc.$653
- plus $3K from 22 others
What the payments were for
- Food & beverage$9,22799%
- Education$1241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $1,525 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $1,137 |
| Lundbeck LLC | 79 | $1,116 |
| Otsuka America Pharmaceutical, Inc. | 47 | $971 |
| Sunovion Pharmaceuticals Inc. | 31 | $744 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $653 |
| Johnson & Johnson | 27 | $583 |
| Alkermes, Inc. | 21 | $417 |
| Teva Pharmaceuticals USA, Inc. | 9 | $366 |
| Vanda Pharmaceuticals Inc. | 17 | $342 |
| Corium, LLC | 11 | $243 |
| Axsome Therapeutics, Inc. | 9 | $188 |
| Bausch Health US, LLC | 10 | $178 |
| Shire North American Group Inc | 12 | $135 |
| Supernus Pharmaceuticals, Inc. | 6 | $113 |
| Corcept Therapeutics | 1 | $104 |
| Neuronetics, Inc. | 3 | $99 |
| Neurocrine Biosciences, Inc. | 1 | $68 |
| Ironshore Pharmaceuticals Inc. | 3 | $61 |
| Tris Pharma Inc | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Scilex Pharmaceuticals Inc. | 1 | $42 |
| Alfasigma USA, Inc. | 2 | $31 |
| Indivior Inc. | 2 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| TMS Neurohealth Centers Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,351 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 59 | $1,481 |
| Perphenazine | 12 | $494 |
| Nortriptyline Hcl | 11 | $333 |
| Trazodone Hcl | 16 | $212 |
| Lorazepam | 15 | $29 |
| Risperidone | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Diego
- Eric ChavezSan Diego$15.5M
- Charmaine SemeniukSan Diego$8.9M
- Jonathan MeyerSan Diego$2.3M
- Vishaal MehraSan Diego$1M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.